Interactions between 3,4-methylenedioxymethamphetamine and ethanol in humans and rodents

Neuropsychobiology

Volumn 60, Issue 3-4, 2009, Pages 188-194

  Mohamed, Wael M Y ^a   Hamida, Sami Ben ^b   Pereira De Vasconcelos, Anne ^b   Cassel, Jean Christophe ^b   Jones, Byron C ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

3,4 methylenedioxymethamphetamine; Activity; Ecstasy; Ethanol; Hyperthermia; Reward

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; AMPHETAMINE; CANNABIS; COCAINE;

DRUG ABUSE; ENVIRONMENTAL TEMPERATURE; HUMAN; HYPERACTIVITY; HYPERTHERMIA; LOCOMOTION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; DRUG INTERACTIONS; ETHANOL; HALLUCINOGENS; HUMANS; MICE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; SPECIES SPECIFICITY;

EID: 70449493474     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000253554     Document Type: Review

References (81)

1. Gross SR: Ecstasy and drug consumption patterns: A Canadian rave population study. Can J Psychiatry 2002; 47: 546-551
2. Schifano F: A bitter pill: overview of ecstasy (MDMA, MDA) related fatalities. Psychopharmacology (Berl) 2004; 173: 242-248
3. NSDUH, Substance Abuse and Mental Health Services Administration: Results from the 2006 National Survey on Drug Use and Health. 2006. http://www.oas.samhsa. gov
4. Wish ED, Fitzelle DB, O'Grady KE, Hsu MH, Arria AM: Evidence for significant polydrug use among ecstasy-using college students. J Am Coll Health 2006; 55: 99-104
5. Landry MJ: MDMA: A review of epidemiologic data. J Psychoactive Drugs 2002; 34: 163-169
6. Drug Enforcement Administration (DEA). 2001. http://thedea.org/ statistics.html
7. Hall AP, Henry JA: Acute toxic effects of Ecstasy (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth 2006; 96: 678-685
8. Schifano F. Corkery J. Deluca P. Oyefeso A. Ghodse A.H. Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK 1994 2003 J Psychopharmacol 2006 20 456-463.
9. Schifano F, Corkery J, Deluca P, Oyefeso A, Ghodse AH: Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994-2003). J Psychopharmacol 2006; 20: 456-463.9 Vollenweider FX, Liechti ME, Gamma A, Greer G, Geyer M: Acute psychological and neurophysiological effects of MDMA in humans. J Psychoactive drugs 2002; 34: 171-184
10. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI: The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 2003; 55: 463-508
11. Gouzoulis-Mayfrank E, Daumann J: The confounding problem of polydrug use in recreational ecstasy/MDMA users: A brief overview. J Psychopharmacol 2006; 20: 188-193
12. Tanner-Smith EE: Pharmacological content of tablets sold as 'ecstasy': results from an online testing service. Drug Alcohol Depend 2006; 83: 247-254
13. Barrett SP, Gross SR, Garand I, Pihl RO: Patterns of simultaneous polysubstance use in Canadian rave attendees. Subst Use Misuse 2005; 40: 1525-1537
14. Lora-Tamayo C, Tena T, Rodriguez A, Moreno D, Sancho JR: The designer drug situation in Ibiza. Forensic Sci Int 2004; 140: 195-206
15. Winstock AR, Griffiths P, Stewart D: Drugs and the dance music scene: A survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 2001; 64: 9-17
16. Topp L, Hando J, Dillon P, Roche A, Solowij N: Ecstasy use in Australia: Patterns of use and associated harm. Drug Alcohol Depend 1999; 55: 105-115
17. Breen C, Degenhardt L, Kinner S, Bruno R, Jenkinson R, Mattews A, Newman J: Alcohol use and risk taking among regular ecstasy users. Subst Use Misuse 2006; 41: 1095-1109
18. Barrett SP, Darredeau C, Pihl RO: Patterns of simultaneous polysubstance use in drug using university students. Hum Psychopharmacol 2006; 21: 255-263
19. Riley SC, James C, Gregory D, Dingle H, Cadger M: Patterns of recreational drug use at dance events in Edinburgh, Scotland. Addiction 2001; 96: 1035-1047
20. Hopper JW, Su Z, Looby AR, Ryan ET, Penetar DM, Palmer CM, Lukas SE: Incidence and patterns of polydrug use and craving for ecstasy in regular ecstasy users: An ecological momentary assessment study. Drug Alcohol Depend 2006; 85: 221-235
21. Hernandez-Lopez C, Farre M, Roset PN, Menoyo E, Pizarro N, Ortuno J, Torrens M, Cami J, de La Torre R: MDMA and alcohol interactions in humans: Psychomotor performance, subjective effects and pharmacokinetics. J Pharmacol Exp Ther 2002; 300: 236-244
22. Riegert C, Wedekind F, Hamdia SB, Rutz S, Rothmaier AK, Jones BC, Cassel JC, Jackisch R: Effects of ethanol and 3,4-methylenedioxymethamphetamine (MDMA) alone or in combination on spontaneous and evoked overflow of dopamine, serotonin and acetylcholine in striatal slices of the rat brain. Int J Neuropsychopharmacol 2008; 11: 743-763
23. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS: Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001; 39: 32-41
24. Bankson MG, Yamamoto BK: Serotonin- GABA interactions modulate MDMA-induced mesolimbic dopamine release. J Neurochem 2004; 91: 852-859
25. Simantov R, Peng W: MDMA (Ecstasy) controls in concert a group of genes involved in GABA neurotransmission. FEBS Lett 2004; 563: 3-6
26. Fischer HS, Zernig G, Schatz DS, Humpel C, Saria A: MDMA ('ecstasy') enhances basal acetylcholine release in brain slices of the rat striatum. Eur J Neurosci 2000; 12: 1385-1390
27. Nair SG, Gudelsky GA: MDMA enhances the release of Ach in the prefrontal cortex and dorsal hippocampus of the rat. Psychopharmacol (Berl) 2006; 184: 182-189
28. Bilsky EJ, Montegut MJ, Nichols ML, Reid LD: CGS 10746B, a novel dopamine release inhibitor, blocks the establishment of cocaine and MDMA conditioned place preferences. Pharmacol Biochem Behav 1998; 59: 215-220
29. Cadoni C, Solinas M, Pisanu A, Zernig G, Acquas E, Di Chiara G: Effect of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on dopamine transmission in the nucleus accumbens shell and core. Brain Res 2005; 1055: 143-148
30. Daniela E, Brennan K, Gittings D, Hely L, Schenk S: Effect of SCH 23390 on 3,4-methylenedioxymethamphetamine hyperactivity and self-administration in rats. Pharmacol Biochem Behav 2004; 77: 745-750
31. Lin HQ, Jackson DM, Atrens DM, Christie MJ, McGregor IS: Serotonergic modulation of 3,4-methylenedioxymethamphetamine (MDMA)-elicited reduction of response rate but not rewarding threshold in accumbal self-stimulation. Brain Res 1997; 744: 351-357
32. Schenk S, Hely L, Lake B, Daniela E, Gittings D, Mash DC: MDMA self-administration in rats: Acquisition, progressive ratio responding and serotonin transporter binding. Eur J Neurosci 2007; 26: 3229-3236
33. Ratzenboeck E, Saria A, Kriechbaum N, Zernig G: Reinforcing effects of MDMA ('ecstasy') in drug-naive and cocaine-trained rats. Pharmacology 2001; 62: 138-144
34. Cornish JL, Shahnawaz Z, Thompson MR, Wong S, Morley KC, Hunt GE, McGregor IS: Heat increases 3,4-methylenedioxymethamphetamine self-administration and social effects in rats. Eur J Pharmacol 2003; 482: 339-341
35. Daniela E, Gittings D, Schenk S: Conditioning following repeated exposure to MDMA in rats: role in the maintenance of MDMA self-administration. Behav Neurosci 2006; 120: 1144-1150
36. Daza-Losada M, Ribeiro Do Couto B, Manzanedo C, Aguilar MA, Rodriguez-Arias M, Minarro J: Rewarding effects and reinstatement of MDMA-induced CPP in adolescent mice. Neuropsychopharmacology 2007; 32: 1750-1759
37. Fantegrossi WE, Godlewski T, Karabenick RL, Stephens JM, Ullrich T, Rice KC, Woods JH: Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ('ecstasy') and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology (Berl) 2003; 166: 202-211
38. Brown PL, Kiyatkin EA: Brain hyperthermia induced by MDMA (ecstasy): Modulation by environmental conditions. Eur J Neurosci 2004; 20: 51-58
39. Saadat KS, Elliott JM, Colado MI, Green AR: Hyperthermic and neurotoxic effect of 3,4- methylenediox ymethamphet amine (MDMA) in guinea pigs. Psychopharmacology (Berl) 2004; 173: 452-453
40. Cumming P, Moller M, Benda K, Minuzzi L, Jakobsen S, Jensen SB, Pakkenberg B, Stark AK, Gramsbergen JB, Andreasen ME, Olsen AK: A PET study of effects of chronic 3,4- methylenediox ymethamphet amine (MDMA, 'ecstasy') on serotonin markers in Göttingen minipig brain. Synapse 2007; 61: 478-487
41. Fiege M, Wappler F, Weissborn R, Gerbershagen MU, Menge M, Schulte A, Esch J: Induction of malignant hyperthermia in susceptible swine by 3,4-methylenedioxymethamphetamine (ecstasy). Anesthesiology 2003; 99: 1132-1136
42. Rosa-Neto P, Olsen AK, Gjedde A, Watanabe H, Cumming P: MDMA-evoked changes in cerebral blood flow in living porcine brain: Correlation with hyperthermia. Synapse 2004; 53: 214-221
43. Pedersen NP, Blessing WW: Cutanous vasoconstriction contributes to hyperthermia induced by 3,4-methylenedioxymethamphetamine (ecstasy) in conscious rabbits. J Neurosci 2001; 21: 8648-8654
44. Freedman RR, Johnson CE, Tancer ME: Thermoregulatory effects of 3,4 methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 2005; 183: 248-256
45. Von Huben SN, Lay CC, Crean RD, Davis SA, Katner SN, Taffe MA: Impact of ambient temperature on hyperthermia induced by 3,4-methylenedioxymethamphetamine in rhesus macaques. Neuropsychopharmacology 2007; 32: 673-681
46. Easton N, Marsden CA: Ecstasy: Are animal data consistent between species and can they translate to humans? J Psychopharmacology 2006; 20: 194-210
47. Henry J.A. Jeffreys K.J. Dawling S. Toxicity and deaths from MDMA Lancet 1992 340 384-387.
48. Henry JA, Jeffreys KJ, Dawling S: Toxicity and deaths from MDMA. Lancet 1992; 340: 384-387.48 Green AR, O'Shea E, Colado MI: A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur J Pharmacol 2004; 500: 3-13
49. Green AR, O'Shea E, Saadat KS, Elliott JM, Colado MI: Studies on the effect of MDMA ('ecstasy') on the body temperature of rats housed at different ambient room temperatures. Br J Pharmacol 2005; 146: 306-312
50. Battaglia G, Yeh S, De Souza EB: MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurons. Pharmacol Biochem Behav 1988; 29: 269-274
51. Lew R, Sabol KE, Chou C, Vosmer GL, Richards J, Seiden LS: Methylene-dioxymethamphetamine- induced serotonin deficits are followed by partial recovery over a 52-week period. II. Radioligand binding and autoradiography studies. J Pharmacol Exp Ther 1996; 276: 855-865
52. Baumann MH, Wang X, Rothman RB: 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: A reappraisal of past and present findings. Psychopharmacology (Berl) 2007; 189: 407-424
53. Wang X, Baumann MH, Xu H, Rothman RB: 3,4-methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein. Synapse 2004; 53: 240-248
54. Sanchez V, O'Shea E, Saadat KS, Elliott JM, Colado MI, Green AR: Effect of repeated ('binge') dosing of MDMA to rats housed at normal and high temperature on neurotoxic damage to cerebral 5-HT and dopamine neurons. J Psychopharmacol 2004; 18: 412-416
55. De Win MM, Reneman L, Reitsma JB, den Heeten GJ, Booij J, van den Brink W: Mood disorders and serotonin transporter density in ecstasy users - the influence of long-term abstention, dose, and gender. Psychopharmacology (Berl) 2004; 173: 367-382
56. McCann UD, Szabo Z, Seckin E, Rosenblatt P, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA: Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C] DASB. Neuropsychopharmacology 2005; 30: 1741-1750
57. Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC: Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users. Br J Psychiatry 1999; 175: 63-69
58. Granado N, Escobedo I, O'Shea E, Colado I, Moratalla R: Early loss of dopaminergic terminals in striosomes after MDMA administration to mice. Synapse 2008; 62: 80-84
59. Granado N, O'Shea E, Bove J, Vila M, Colado MI, Moratalla R: Persistent MDMA-induced dopaminergic neurotoxicity in the striatum and substantia nigra of mice. J Neurochem 2008; 107: 1102-1112
60. Johnson EA, O'Callaghan JP, Miller DB: Brain concentrations of d-MDMA are increased after stress. Psychopharmacology (Berl) 2004; 173: 278-286
61. Ben Hamida SB, Tracqui A, de Vasconcelos AP, Szwarc E, Lazarus C, Kelche C, Jones BC, Cassel JC: Ethanol increases the distribution of MDMA to the rat brain: Possible implications in the ethanol-induced potentiation of the psychostimulant effects of MDMA. Int J Neuropsychopharmacol 2009; 12: 749-759
62. Ben Hamida SB, Bach S, Plute E, Jones BC, Kelche C, Cassel JC: Ethanol-ecstasy (MDMA) interactions in rats: Preserved attenuation of hyperthermia and potentiation of hyperactivity by ethanol despite prior ethanol treatment. Pharmacol Biochem Behav 2006; 84: 162-168
63. Ben Hamida SB, Plute E, Cosquer B, Kelche C, Jones BC, Cassel JC: Interactions between ethanol and cocaine, amphetamine, or MDMA in the rat: Thermoregulatory and locomotor effects. Psychopharmacology (Berl) 2008; 197: 67-82
64. Cassel JC, Jeltsch H, Koenig J, Jones BC: Locomotor and pyretic effects of MDMA-ethanol association in rats. Alcohol 2004; 34: 285-289
65. Cassel JC, Riegert C, Rutz S, Koenig J, Rothmaier K, Cosquer B, Lazarus C, Birthelmer A, Jeltsch H, Jones BC, Jackisch R: Ethanol, 3,4- methylenedioxymethamphetamine (ecstasy) and their combination: Long-term behavioral, neurochemical and neuropharmacological effects in the rat. Neuropsychopharmacology 2005; 30: 1870-1882
66. Cassel JC, Ben Hamida S, Jones BC: Attenuation of MDMA-induced hyperthermia by ethanol in rats depends on ambient temperature. Eur J Pharmacol 2007; 571: 152-155
67. Ben Hamida S, Plute E, Bach S, Lazarus C, Tracqui P, Kelche C, de Vasconcelos AP, Jones BC, Cassel JC: Ethanol-MDMA interactions in rats: The importance of interval between repeated treatments in biobehavioral tolerance and sensitization to the combination. Psychopharmacology (Berlin) 2007; 192: 555-569
68. Jones BC, Ben-Hamida S, Pereira de Vasconcelos A, Kelche C, Lazarus C, Jackisch R, Cassel J-C: Effects of ethanol and ecstasy on conditioned place preference in the rat. J Psychopharmacol, in press
69. Izco M, Orio L, O'Shea E, Colado MI: Binge ethanol administration enhances the MDMA-induced long-term 5-HT neurotoxicity in rat brain. Psychopharmacology (Berl) 2007; 189: 459-470
70. Jones BC, Cassel JC: Ethanol and MDMA: A comment on the paper by Izco et al. Psychopharmacology (Berl) 2007; 191: 387-388
71. O'shea E, Colado MI: Factors contributing to the enhancement of MDMA-induced 5-HT depletion by ethanol: A reply to Byron and Cassel. Psychopharmacology (Berl) 2007; 190: 581-582
72. Pontes H, Sousa C, Silva R, Fernandes E, Carmo H, Remiao F, Carvalho F, Bastos ML: Synergistic toxicity of ethanol and MDMA towards primary cultured rat hepatocytes. Toxicology 2008; 254: 42-50
73. Pontes H, Duarte JA, de Pinho PG, Soares ME, Fernandes E, Dinis-Oliveira RJ, Sousa C, Silva R, Carmo H, Casal S, Remiao F, Carvalho F, Bastos ML: Chronic exposure to ethanol exacerbates MDMA-induced hyperthermia and exposes liver to severe MDMA-induced toxicity in CD1 mice. Toxicology 2008; 252: 64-71
74. Pontes H, Santos-Marques MJ, Fernandes E, Duarte JA, Remiao F, Carvalho F, Bastos ML: Effect of chronic ethanol exposure on the hepatotoxicity of ecstasy in mice: An ex vivo study. Toxicol In Vitro 2008; 22: 910-920
75. Dumont GJ, Wezenberg E, Valkenberg MM, de Jong CA, Buitelaar JK, van Gerven JM, Verkes RJ: Acute neuropsychological effects of MDMA and ethanol (co)administration in healthy volunteers. Psychopharmacology (Berl) 2008; 197: 465-474
76. Kuypers KP, Samyn N, Ramaekers JG: MDMA and alcohol effects, combined and alone, on objective and subjective measures of actual driving performance and psychomotor function. Psychopharmacology (Berl) 2006; 187: 467-475
77. Ramaekers JG, Kuypers KP: Acute effects of 3,4- methylenedioxymethamphetamine (MDMA) on behavioral measures of impulsivity: Alone and in combination with alcohol. Neuropsychopharmacology 2006; 31: 1048-1055
78. Cassel JC, Hamida SB, Jones BC: Ethanol and MDMA: A comment on the paper by Dumont et al. Psychopharmacology (Berl) 2008; 200: 305-306
79. Dumont GJ, Verkes RJ, Buitelaar JK, van Gerven JM: Response to the comments by Cassel et al. Psychopharmacology (Berl) 2008; 200: 451-452
80. Pacifici R, Zuccaro P, Hernandez LC, Pichini S, Di Carlo S, Farre M, Roset PN, Ortuno J, Segura J, de la Torre R: Acute effects of 3,4- methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans. J Pharmacol Exp Ther 2001; 296: 207-215
81. Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, Ortuno J, Segura J, de la Torre R: Immunomodulating properties of MDMA alone and in combination with alcohol: A pilot study. Life Sci 1999; 65:L309-L316